secukinumab + candin

Secukinumab + candin is a hypothetical combination of secukinumab, a human monoclonal antibody targeting interleukin-17A, and a drug from the candin class, which refers to the echinocandin antifungal agents. Secukinumab is primarily used as an immunomodulatory agent for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, hidradenitis suppurativa, and enthesitis-related arthritis. It works by inhibiting interleukin-17A, thereby reducing inflammation and autoimmune activity[1][3][5][7]. Echinocandins, often generically referred to as "candin" drugs, inhibit fungal cell wall biosynthesis by noncompetitive inhibition of 1,3-β-glucan synthase, resulting in antifungal action effective mainly against Candida species[2][4]. There is no approved or documented pharmaceutical product or combination therapy marketed as secukinumab + candin; thus, this would represent a theoretical or investigational combination of an immunomodulator and an antifungal agent.

Other names

secukinumab + candin